leisure time -WSS

leisure time

author：comprehensive 2025-08-28 04:23:04 - browse：8564

Susan Galbraith of AstraZeneca gestures while speaking – pharma coverage from STAT — Susan Galbraith, AstraZeneca’s head of cancer research and development, speaks at a STAT event in 2023. Marie Miller for STAT

CHICAGO — AstraZeneca’s head of cancer research and development, Susan Galbraith, is British, and prone to a particularly British style of understatement. She doesn’t boast loudly. But she did come to this year’s annual meeting of the American Society of Clinical Oncology wearing a small lapel pin with the numeral 6 and the “AZ” corporate logo.

That pin represents the number of years in a row that the London-based drug giant has had a presentation in the ASCO plenary, the conference’s biggest showcase for new data. This year, the company has two.

Scientific credibility is great, of course. But AstraZeneca’s shareholders want something else: return on investment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： What PEPFAR has meant on the ground in Ukraine

WSS

Supreme Court wrestles with OxyContin maker's bankruptcy deal

Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Americans' trust in science, scientist continues decline: Report

CRISPR base editing slashes cholesterol levels in monkeys

The United States is paying nearly triple for new Covid vaccines

STAT letters to the editor on burnt

focus

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

In diabetes hearing, Sanders takes on a new foe: food makers

Heart attack and stroke risk calculators need revising

SCOTUS to consider access to abortion pill mifepristone

BioMarin wins approval for gene therapy to treat hemophilia A

Will an HIV vaccine ever be a reality?

BioMarin wins approval for gene therapy to treat hemophilia A

European officials brace for rough respiratory virus season

Duchenne breakthrough therapy leaves behind pioneering families

FDA needs staff influx to meet gene therapy needs, Marks says

leisure time

After sickle

Spinal cord stimulation reduces pain in amputees, study finds

Will an HIV vaccine ever be a reality?

What causes an itch? Researchers may have solved the mystery

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

What causes an itch? Researchers may have solved the mystery

entertainment

leisure time

knowledge

hotspot